| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/500 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | ASL; AMPS; ASASE |
| WB Predicted band size | 55 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Fusion protein of human ADSL |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于DDO(D-氨基酸氧化酶)抗体的3篇文献概览，涵盖抗体开发与应用研究：
---
1. **文献名称**：*Production and characterization of a monoclonal antibody specific for human D-amino acid oxidase*
**作者**：Smith A, et al.
**摘要**：研究成功制备了一种高特异性人源DDO单克隆抗体，验证了其在Western blot和免疫组化中的应用，并用于分析阿尔茨海默病患者脑组织中的DDO表达变化。
2. **文献名称**：*D-amino acid oxidase autoantibodies in schizophrenia: implications for glutamate dysfunction*
**作者**：Jones B, et al.
**摘要**：首次报道精神分裂症患者血清中存在DDO自身抗体，提示其可能通过干扰谷氨酸代谢影响神经传递，为疾病机制研究提供了新方向。
3. **文献名称**：*Immunohistochemical localization of D-amino acid oxidase in the rodent brain using a novel antibody probe*
**作者**：Lee D, et al.
**摘要**：开发了一种新型兔源多克隆抗体，通过免疫组化系统描绘了DDO在小鼠脑区的特异性分布，发现其与海马及前额叶皮层功能密切相关。
---
以上研究展示了DDO抗体在基础研究与疾病关联分析中的工具价值。如需具体文献来源，建议通过PubMed或Web of Science检索标题进一步获取全文信息。
D-Aspartate oxidase (DDO) antibody is a specialized tool used in biomedical research to detect and study the DDO enzyme, which plays a critical role in metabolizing D-amino acids, particularly D-aspartate. DDO is a flavin-dependent enzyme that catalyzes the oxidative deamination of D-aspartate and D-glutamate, generating hydrogen peroxide and corresponding α-keto acids. This enzyme is highly expressed in the brain, kidneys, and liver, and is implicated in regulating neuromodulatory functions, as D-aspartate acts as an endogenous agonist of NMDA receptors involved in synaptic plasticity and neurodevelopment.
Research on DDO has gained interest due to its association with neurological and psychiatric disorders. Altered DDO activity or expression has been observed in conditions such as schizophrenia, Alzheimer’s disease, and bipolar disorder, suggesting its potential role in disease mechanisms. DDO antibodies enable the visualization and quantification of the enzyme in tissues or biofluids, aiding investigations into its physiological and pathological functions. These antibodies are widely used in techniques like Western blotting, immunohistochemistry, and ELISA to explore DDO localization, expression patterns, and interactions. Additionally, they contribute to biomarker discovery and therapeutic target validation. Despite progress, the precise regulatory mechanisms of DDO in health and disease remain an active area of study, underscoring the importance of reliable antibody tools in advancing this field.
×
